By Gregory Lopes
THE WASHINGTON TIMES
February 27, 2007
The chairman of the federal panel that recommended the new cervical-cancer
vaccine for pre-teen girls says lawmakers should not make the inoculation
mandatory, as the District and more than 20 states, including Virginia, are
considering.
Dr. Jon Abramson, chairman of the
Centers for Disease Control and Prevention's advisory committee on immunization
practices (ACIP), also said he and panel members told Merck & Co., the drug
Gardasil's maker, not to lobby state lawmakers to require the vaccine for school
attendance.
"I told Merck my personal opinion that
it shouldn't be mandated," Dr. Abramson told The Washington Times. "And they
heard it from other committee members."
Dr. Abramson
said he opposes mandating Gardasil, which prevents the cervical-cancer-causing
human papillomavirus (HPV), because the sexually transmitted HPV is not a
contagious disease like measles and he is not sure states can afford to
inoculate all students.
"The vaccines out there now
are for very communicable diseases. A child in school is not at an increased
risk for HPV like he is measles," Dr. Abramson said.
In addition, Dr. Abramson said a discussion about
making the vaccine mandatory should not be had until states show the money is
available to vaccinate every child, adding, "I don't see that yet."
Taken in a series of three shots at $120 each,
Gardasil is the most expensive vaccine on the market. About 45 percent of
children would be eligible for free vaccines from the federal Vaccinations for
Children program, while the other 55 percent would depend on the state programs
and insurance companies.
The ACIP, a 15-member panel
charged with developing vaccine schedules and dosages, recommended Gardasil for
11- and 12-year-olds in July, spurring Merck's lobbying efforts and the
legislative push to make the HPV vaccine mandatory for sixth-grade girls.
Merck suspended its lobbying efforts last week amid
criticism from parents, who said it would interfere with control over their
children, and from conservative groups that said it would encourage premarital
sex.
Merck responded yesterday to Dr. Abramson's
comments with a statement it had made previously.
"We have had ongoing discussions with a number of
key public health experts and listened to their thoughts regarding the timing
for school requirements of the HPV vaccine. We do not want any misperception
about Merck's role to distract from the ultimate goal of fighting cervical
cancer, so Merck has re-evaluated its approach at the state level and we will
not lobby for school requirements for Gardasil."
Gardasil is nearly 100 percent effective against two
strains of HPV that lead to 70 percent of cervical cancer cases in the United
States. Nearly 11,000 cervical-cancer cases occur in the U.S. each year, killing
more than 3,700, according to the American Cancer Society.
Privacy
Policy | About TWT | Community
Relations | Search |
Site
Map | Contact Us
Advertise | Subscription
Services | TWT
Gift Shop
All site contents copyright © 2007 The Washington Times, LLC.